First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective study
PD-1 blockades combined with TKIs appeared an effective and safe choice in first-line treatment of mnccRCC, especially in individuals with good performance status, non-chromophobe/Mit family translocation histologies, and intermediate/poor IMDC classification.
Authors
- Jiwei Huang
- Cheoklong NG
- Hui Han
- Xuhao Liu
- Wensu Wei
- Xi Zhong
- Taile Jing
- Zhiling Zhang
- Yulu Peng
- Pei Dong
- Tingxuan Huang
- Minfeng Chen
Institutions
- Central South University (CN)
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Xiangya Hospital Central South University (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1007/s00262-025-04293-9
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- National Postdoctoral Program for Innovative Talents